Compare CVEO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVEO | TTRX |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.1M | 298.8M |
| IPO Year | 2013 | 2025 |
| Metric | CVEO | TTRX |
|---|---|---|
| Price | $36.06 | $9.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $44.41 | $25.00 |
| AVG Volume (30 Days) | ★ 216.7K | 83.6K |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.90 | N/A |
| Revenue Next Year | $5.02 | $900.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.97 | $2.57 |
| 52 Week High | $38.06 | $16.45 |
| Indicator | CVEO | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 42.37 |
| Support Level | $31.37 | $8.75 |
| Resistance Level | $38.06 | $11.17 |
| Average True Range (ATR) | 2.23 | 0.98 |
| MACD | 0.35 | 0.06 |
| Stochastic Oscillator | 73.29 | 39.55 |
Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, and Australia. It derives maximum revenue from Australia.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.